As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new Phase 3 data for Dupixent (dupilimab) in the treatment of severe atopic dermatitis in paediatric patients aged between six and 11 years old.
When used in combination with standard-of-care topical corticosteroids (TCS), 33% of patients receiving Dupixent every four weeks and 30% receiving it every two weeks achieved clear or almost clear skin with an Investigator’s Global Assessment (IGA) score of 0 or 1, compared to 11% with placebo.
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
